FcRn Inhibitor

Viridian is advancing a potentially best-in-class neonatal Fc receptor (FcRn) inhibitor portfolio, a validated mechanism with the potential to reach a broad range of autoantibody-mediated autoimmune diseases.

VRDN-008

VRDN-008 is a novel FcRn inhibitor designed for convenient, at-home subcutaneous self-administration. VRDN-008 aims to pair immunoglobulin G (IgG) reduction with extended half-life technology to potentially enable deep IgG reductions that are more sustained than existing anti-FcRn therapies. VRDN-008 has a half-life of 15-18 days, up to 6 times that of first generation Fc fragments, and demonstrated deep and sustained IgG reductions through 8 weeks, with 74% reduction at peak, after dosing in healthy volunteers.

Viridian aims to develop VRDN-008 in multiple autoantibody-mediated autoimmune diseases and plans to initiate at least one registrational trial in 2027, starting with myasthenia gravis in mid-2027.